Illumina Approves Key Proposals at Annual Meeting

Illumina ( (ILMN) ) has provided an update.

On May 21, 2025, Illumina, Inc. held its annual meeting of stockholders where several key proposals were approved. These included the election of eleven directors to the board, the ratification of Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 28, 2025, the approval of executive compensation, and the amendment of the 2015 Stock and Incentive Plan. These decisions reflect the company’s ongoing governance and operational strategies, potentially impacting its market positioning and stakeholder relations.

The most recent analyst rating on (ILMN) stock is a Buy with a $160.00 price target. To see the full list of analyst forecasts on Illumina stock, see the ILMN Stock Forecast page.

Spark’s Take on ILMN Stock

According to Spark, TipRanks’ AI Analyst, ILMN is a Neutral.

Illumina’s overall score is hampered by poor financial performance and challenging valuation metrics. Despite strong innovation and specific product successes, broader market and geopolitical challenges weigh heavily on the outlook. Technical analysis suggests a neutral stance, reflecting consolidation in stock price movements. The mixed outlook from the earnings call highlights both opportunities and risks, influencing the overall score.

To see Spark’s full report on ILMN stock, click here.

More about Illumina

Illumina, Inc. operates in the biotechnology industry, focusing on the development and manufacturing of life science tools and integrated systems for large-scale analysis of genetic variation and function.

Average Trading Volume: 2,385,602

Technical Sentiment Signal: Strong Sell

Current Market Cap: $12.75B

Learn more about ILMN stock on TipRanks’ Stock Analysis page.